We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Merz Gets Untitled Letter for Inflated Marketing Claims, Risk Omissions
Merz Gets Untitled Letter for Inflated Marketing Claims, Risk Omissions
August 7, 2013
The FDA flagged Merz Pharmaceuticals for a web page and banners that the agency says ignore risk information and make overblown claims surrounding its anti-fungal treatment Naftin.